271 related articles for article (PubMed ID: 25638546)
1. Anti-PD-L1 antibody active in metastatic bladder cancer.
Brower V
Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
[No Abstract] [Full Text] [Related]
2. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Sundararajan S; Vogelzang NJ
Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
[TBL] [Abstract][Full Text] [Related]
3. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
4. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: a new frontier in bladder cancer.
Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Krishnamurthy A; Jimeno A
Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Inman BA; Longo TA; Ramalingam S; Harrison MR
Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
9. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
Hansen AR; Siu LL
JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
[No Abstract] [Full Text] [Related]
11. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
Afreen S; Dermime S
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):1-17. PubMed ID: 24398144
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
13. The science of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
[No Abstract] [Full Text] [Related]
14. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
15. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for bladder cancer: rediscovering an old friend.
Voskoboynik M; Rudman S; Arkenau HT; Hughes S; Chowdhury S
BJU Int; 2016 May; 117(5):721-4. PubMed ID: 26389688
[No Abstract] [Full Text] [Related]
17. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1 for metastatic triple-negative breast cancer.
Gibson J
Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25936988
[No Abstract] [Full Text] [Related]
19. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
